Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Consolidated Net Income: 2009-2025

Historic Consolidated Net Income for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -$27.4 million.

  • Myriad Genetics' Consolidated Net Income fell 23.98% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.5 million, marking a year-over-year decrease of 245.26%. This contributed to the annual value of -$127.3 million for FY2024, which is 51.65% up from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Consolidated Net Income is -$27.4 million, which was up 91.71% from -$330.5 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Consolidated Net Income high stood at $24.6 million for Q3 2021, and its period low was -$330.5 million during Q2 2025.
  • For the 3-year period, Myriad Genetics' Consolidated Net Income averaged around -$68.1 million, with its median value being -$36.7 million (2024).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first soared by 261.84% in 2021, then tumbled by 800.54% in 2025.
  • Myriad Genetics' Consolidated Net Income (Quarterly) stood at -$7.6 million in 2021, then slumped by 456.58% to -$42.3 million in 2022, then climbed by 26.24% to -$31.2 million in 2023, then tumbled by 36.22% to -$42.5 million in 2024, then decreased by 23.98% to -$27.4 million in 2025.
  • Its Consolidated Net Income stands at -$27.4 million for Q3 2025, versus -$330.5 million for Q2 2025 and -$100,000 for Q1 2025.